Nela Duke Ekpenyong

54gene addresses the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Ingressive Capital is a $10M VC targeting tech-enabled startups in Nigeria, Kenya, Ghana and Egypt. The fund is Delaware-incorporated and headquartered in Nigeria.  We target 10% ownership in Pre-Seed to Seed tech-enabled companies based in Sub-Saharan Africa with typical check sizes of up to $400k. We provide follow-on funding with our own investor base, who run some of the leading funds in the world. We look for post-launch founders with great products, solving big problems and we work with them on ways to grow and scale through business development, partnerships and financial support.

54gene addresses the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.